In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid

Author(s): Rajeev K. Singla, Luciana Scotti, Ashok K. Dubey*

Journal Name: Current Neuropharmacology

Volume 15 , Issue 8 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Background: Ursolic acid, a bioactive pentacyclic triterpenoid had been evaluated for its interaction with the neurological targets associated with antidepressant drugs. Current study was to mechanistically analyze the probable site of action for ursolic acid on the target proteins.

Methods: Ursolic acid has been docked with monoamine oxidase isoforms: MAO-A and MAO-B, LeuT (homologue of SERT, NET, DAT) and Human C-terminal CAP1 using GRIP docking methodology.

Results: Results revealed its non-selective antidepressant action with strong binding affinity towards LeuT and MAO-A proteins, which was found to be comparable with the reference ligands like chlorgyline, clomipramine, sertraline and deprenyl/selegiline.

Conclusion: Significant binding affinity of ursolic acid was seen with MAO-A, which indicated its potential role in other neurological disorders, for example, Alzheimer's disease and Parkinson disease besides depression.

Keywords: Ursolic acid, MAO-A inhibitor, MAO-B inhibitor, adenylyl cylase inhibitor, LeuT inhibitor, docking studies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1100 - 1106]
Pages: 7
DOI: 10.2174/1570159X14666161229115508
Price: $65

Article Metrics

PDF: 29
PRC: 2